Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

Recombinant SMAD4 / DPC4 (Pancreatic Adenocarcinoma Marker / Tumor Suppressor) Antibody [SMAD4/7905R]

In Stock
Catalog Number Formulation Size Price
4089-RBM25-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$229.00
4089-RBM25-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$519.00
4089-RBM25-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$519.00
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol Note
Immunohistochemistry (IHC)
1-2ug/ml
30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes

Summary

Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF-Î � family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80% of cases of pancreatic adenocarcinoma, but rarely in endometrial (0%), colorectal (0%), ovarian (3%), lung (0%), breast (2%) adenocarcinomas, and malignant melanoma (4%). SMAD4is an important marker for confirming a diagnosis of pancreatic adenocarcinoma.

Product Properties & Targets

Host
Rabbit
Applications
Species Reactivity
Isotype / Light Chain
IgG / Kappa
Cellular Localization
Nucleus. Cytoplasm. Cytoplasmic in absence of ligand. Migrates to nucleus when complexed with R-SMAD.
Gene Name
Positive Control
Human pancreatic ductal adenocarcinoma.
Immunogen
Recombinant fragment (around aa400-552) of human SMAD4 protein (exact sequence is proprietary)
Alternate Names
Mothers against decapentaplegic homolog 4, Deletion target in pancreatic carcinoma 4, SMAD family member 4, Deleted in Pancreatic Carcinoma 4 (DPC4); JIP; MAD homolog 4 (MADH4); Mothers against decapentaplegic homolog 4 (MADH4); Mothers against DPP homolog 4; MYHRS; SMAD4

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
SMAD4/7905R
Chromosome Location
18q21.2
Mol. Weight of Antigen
61kDa

Functions

  • In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac-specific gene expression. Binds to SMAD binding elements (SBEs) (5'-GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions (By similarity). Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling (PubMed:25514493). Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for synergistic transcriptional activity in response to TGF-beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.

Key References

  • Iacobuzio-Donahue CA, et al. Am J Surg Pathol. 2000; 24:1544-8.
  • Hornick JL, et al. Am J Surg Pathol. 2005; 29:381-9.

PubMed Links

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “Recombinant SMAD4 / DPC4 (Pancreatic Adenocarcinoma Marker / Tumor Suppressor) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK